- Home
- ASPI vs LXRX Comparison
ASPI vs LXRX Comparison
Compare ASPI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASPI | LXRX |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.3M | 660.9M |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ASPI | LXRX |
|---|---|---|
| Price | $4.17 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.00 | $4.15 |
| AVG Volume (30 Days) | ★ 4.9M | 2.3M |
| Earning Date | 05-19-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | $4,144,226.00 | ★ $49,803,000.00 |
| Revenue This Year | $108.31 | N/A |
| Revenue Next Year | $403.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 857.04 | 60.24 |
| 52 Week Low | $3.92 | $0.45 |
| 52 Week High | $14.49 | $1.83 |
Technical Indicators
Market Signals| Indicator | ASPI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 51.80 |
| Support Level | $4.04 | $1.47 |
| Resistance Level | $6.65 | $1.65 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 17.87 | 43.21 |
Price Performance
Historical ComparisonAbout ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.